News

Under the terms of the purchase agreements, PharmAthene will sell an aggregate of 2.12 million newly issued shares of its common stock at $2.60 per share and warrants

The trial met its primary efficacy endpoint, the mean change from baseline to week 12 (or last visit) of average weekly pain intensity scores, and the results were

Currently Sherman is a senior vice president and general manager. He will report to John E. McGlade, chairman, president and chief executive officer. He will have responsibility for

“Prometheus had another record year in 2008, our 12th consecutive year of sales growth,” said Joseph M. Limber, President And Chief Executive Officer of Prometheus. “In addition, we

Vetter Pharma-Fertigung, a provider of aseptically pre-filled injection systems, has formed a new subsidiary, Vetter Pharma International. With a scheduled launch date of April 1, 2009, Vetter Pharma

GVK Biosciences, an Indian contract research organization, has obtained approval from the Ministry of Health of Turkey for bioequivalence studies. This approval enables GVK Biosciences to cater to

The companies will also continue joint product development activities ensuring customers have continued access to new coagulation technology. “Our shared value to deliver quality products and services that

Net sales for the fourth quarter of 2008 were $2.2 million, down $1.2 million, or 31.6% from $3.3 million reported in the fourth quarter of 2007. Operating loss

Medivation, a biopharmaceutical company, has received the FDA approval to begin a pivotal Phase III trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant